PLRZ Polyrizon Ltd. Annual reports only
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1893645 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-115.9%
TTM EPS YoY-99.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-25.4%
ROA-24.7%
ROIC (approx.)-44.0%
Asset turnover—
Leverage & solvency
Liabilities / assets2.1%
Debt / equity0.00x
Current ratio29.03x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.36x
Accruals ratio8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | — |
| R&D expense | $2.13M | $534,000 | $332,000 | $347,000 |
| SG&A expense | $4.12M | $768,000 | $303,000 | $548,000 |
| Operating income | -$6.25M | -$1.30M | -$635,000 | -$895,000 |
| Net income | -$3.33M | -$1.54M | -$600,000 | -$779,000 |
| EBITDA | -$5.91M | -$1.18M | -$631,000 | -$890,000 |
| EPS (basic) | 4.90 | 805.20 | 494.40 | 0.60 |
| EPS (diluted) | 4.90 | 805.20 | 494.40 | 0.60 |
| Weighted avg. shares (diluted) | 680,380 | 1,994 | 1,354 | 1.31M |
| Balance sheet | ||||
| Cash & equivalents | $1.31M | $2.55M | $4,000 | $36,000 |
| Short-term investments | — | — | $37,000 | — |
| Current assets | $12.86M | $2.65M | $54,000 | — |
| PP&E, net | $12,000 | $10,000 | $12,000 | — |
| Intangibles | $2.55M | $2.88M | — | — |
| Total assets | $21.44M | $5.55M | $559,000 | — |
| Current liabilities | $443,000 | $261,000 | $502,000 | — |
| Total liabilities | $443,000 | $261,000 | $502,000 | — |
| Shareholders' equity | $20.99M | $5.29M | -$191,000 | -$900,000 |
| Shares outstanding | 1.61M | 2,796 | 2.55M | — |
| Cash flow statement | ||||
| Operating cash flow | -$4.53M | -$1.15M | -$537,000 | -$1.13M |
| Capital expenditure | $7,000 | — | — | $3,000 |
| Free cash flow | -$4.54M | — | — | -$1.14M |
| Investing cash flow | -$16.53M | $29,000 | — | -$3,000 |
| Financing cash flow | $19.81M | $3.67M | $505,000 | $648,000 |
| Depreciation & amortization | $342,000 | $118,000 | $4,000 | $5,000 |
| Stock-based compensation | $1.31M | $51,000 | $100,000 | $130,000 |
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.